scholarly journals Oral Controlled Delivery of Natural Compounds Using Food-Grade Polymer Microparticles

2020 ◽  
Vol 01 ◽  
Author(s):  
Claudia Curcio ◽  
Angela Bonaccorso ◽  
Teresa Musumeci ◽  
Rosario Pignatello

Background:: targeted drug delivery to colon is a strategical approach for the local cure of inflammation bowel diseases (IBD) and other syndromes like colon cancer. Research is actively focusing on possible alternative and safer therapies to conventional drugs, based on herbal remedies and other natural products. In particular, colon-targeted drug delivery systems (CDDS) offer the opportunity to protect the active compound along the way to the colon. Drug release and absorption, and even degradation should not occur in the stomach and small bowel, but a selective release should star once the system moves to the colonic area. Objective:: this work aims at evaluating the gastro-resistant properties of new food-grade methacrylic resins (Eudraguard®), used not as coating materials, but after the formation of microparticles, to achieve a delayed and targeted release of a model drug, resveratrol (RVT), to the ileo-colonic area. Methods:: microparticles were produced by an emulsion-solvent evaporation technique (ESE) and characterized by solid-state analytical methods. RVT release profiles were assessed in vitro using a pH-change procedure, able to simulate the transit of the carrier along the gastro-intestinal tract. Results:: Eudraguard® Biotic can form microparticles with a very high encapsulation efficiency for RVT; the polymeric matrix is able to limit the diffusion of the drug at gastric and gut pH conditions, while a higher release was achieved at pH 7.4. Conversely, using the Eudraguard® Control resin, alone or blended with the former polymer, did not allow to achieve a controlled release of RVT at the various pH values. Conclusion:: food-grade Eudraguard® matrices can be proposed, and would deserve further investigations, as polymeric materials for the preparation of micrometric matrices or pellets for the oral controlled release of natural active ingredients to the ileo-colonic area.

Pharmaceutics ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 581 ◽  
Author(s):  
Lixin Wang ◽  
Yunmei Song ◽  
Ankit Parikh ◽  
Paul Joyce ◽  
Rosa Chung ◽  
...  

Delta inulin, also known as microparticulate inulin (MPI), was modified by covalently attaching doxorubicin to its nanostructured surface for use as a targeted drug delivery vehicle. MPI is readily endocytosed by monocytes, macrophages, and dendritic cells and in this study, we sought to utilize this property to develop a system to target anti-cancer drugs to lymphoid organs. We investigated, therefore, whether MPI could be used as a vehicle to deliver doxorubicin selectively, thereby reducing the toxicity of this antibiotic anthracycline drug. Doxorubicin was covalently attached to the surface of MPI using an acid–labile linkage to enable pH-controlled release. The MPI-doxorubicin conjugate was characterized using FTIR and SEM, confirming covalent attachment and indicating doxorubicin coupling had no obvious impact on the physical nanostructure, integrity, and cellular uptake of the MPI particles. To simulate the stability of the MPI-doxorubicin in vivo, it was stored in artificial lysosomal fluid (ALF, pH 4.5). Although the MPI-doxorubicin particles were still visible after 165 days in ALF, 53% of glycosidic bonds in the inulin particles were hydrolyzed within 12 days in ALF, reflected by the release of free glucose into solution. By contrast, the fructosidic bonds were much more stable. Drug release studies of the MPI-doxorubicin in vitro, demonstrated a successful pH-dependent controlled release effect. Confocal laser scanning microscopy studies and flow cytometric analysis confirmed that when incubated with live cells, MPI-doxorubicin was efficiently internalized by immune cells. An assay of cell metabolic activity demonstrated that the MPI carrier alone had no toxic effects on RAW 264.7 murine monocyte/macrophage-like cells, but exhibited anti-cancer effects against HCT116 human colon cancer cells. MPI-doxorubicin had a greater anti-cancer cell effect than free doxorubicin, particularly when at lower concentrations, suggesting a drug-sparing effect. This study establishes that MPI can be successfully modified with doxorubicin for chemotherapeutic drug delivery.


2013 ◽  
Vol 5 (15) ◽  
pp. 6909-6914 ◽  
Author(s):  
Guodong Liu ◽  
He Shen ◽  
Jinning Mao ◽  
Liming Zhang ◽  
Zhen Jiang ◽  
...  

2021 ◽  
Vol 104 ◽  
pp. 93-105
Author(s):  
Sikhumbuzo Charles Kunene ◽  
Kuen-Song Lin ◽  
Meng-Tzu Weng ◽  
Maria Janina Carrera Espinoza ◽  
Chun-Ming Wu

2021 ◽  
Vol 28 (3) ◽  
pp. 359-359
Author(s):  
Hongfei Liu ◽  
Jie Zhu ◽  
Pengyue Bao ◽  
Yueping Ding ◽  
Jiapeng Wang ◽  
...  

The authors are regretful for submitting and approving the publication of incorrect Figure 4 in this article. Below is the corrected version along with the revised caption. The electronic version of the article has already been corrected.


ChemNanoMat ◽  
2019 ◽  
Vol 5 (4) ◽  
pp. 479-487 ◽  
Author(s):  
Ting Yang ◽  
Jing‐Li Huang ◽  
Yi‐Ting Wang ◽  
An‐Qi Zheng ◽  
Yang Shu ◽  
...  

2021 ◽  
Vol 32 (20) ◽  
pp. 205604
Author(s):  
Zhuoxian Mai ◽  
Jiali Chen ◽  
Qingyun Cao ◽  
Yang Hu ◽  
Xianming Dong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document